Addus HomeCare (NASDAQ:ADUS) Earns Buy Rating from Analysts at UBS Group

Key Points

• Analysts at UBS Group have initiated coverage of Addus HomeCare with a "buy" rating and a price target of $145.00, indicating a potential upside of 25.90% from the last close.
• The company reported a 21.8% year-over-year increase in revenue, with an EPS of $1.49 surpassing analysts' expectations.
• Insider trading activity included significant sales, with Director Veronica Hill-Milbourne selling shares totaling approximately $180,555 and EVP Brian Poff selling shares worth nearly $904,070.

Stock analysts at UBS Group began coverage on shares of Addus HomeCare (NASDAQ:ADUS - Get Free Report) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage set a "buy" rating and a $145.00 price target on the stock. UBS Group's price target points to a potential upside of 25.90% from the company's previous close.

A number of other equities research analysts have also recently weighed in on ADUS. Royal Bank Of Canada boosted their price target on shares of Addus HomeCare from $133.00 to $134.00 and gave the company an "outperform" rating in a research report on Friday, August 22nd. JMP Securities reissued a "market outperform" rating and issued a $150.00 price target on shares of Addus HomeCare in a research report on Wednesday, July 16th. Wall Street Zen raised shares of Addus HomeCare from a "hold" rating to a "buy" rating in a research report on Sunday, June 29th. Macquarie reissued an "outperform" rating and issued a $133.00 price target on shares of Addus HomeCare in a research report on Tuesday, June 10th. Finally, TD Cowen boosted their price target on shares of Addus HomeCare from $135.00 to $139.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $139.11.

Addus HomeCare Price Performance

Addus HomeCare stock opened at $115.17 on Tuesday. The stock has a market cap of $2.12 billion, a P/E ratio of 25.42, a price-to-earnings-growth ratio of 1.75 and a beta of 0.85. The company has a fifty day simple moving average of $112.10 and a 200-day simple moving average of $106.91. Addus HomeCare has a 12-month low of $88.96 and a 12-month high of $136.72. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.17.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $1.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.04. The business had revenue of $349.44 million during the quarter, compared to analysts' expectations of $345.71 million. Addus HomeCare had a net margin of 6.51% and a return on equity of 9.39%. The company's revenue for the quarter was up 21.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.35 EPS. Equities analysts expect that Addus HomeCare will post 4.59 EPS for the current fiscal year.

Insider Activity

In other news, Director Veronica Hill-Milbourne sold 1,571 shares of the company's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $114.93, for a total value of $180,555.03. Following the completion of the sale, the director directly owned 5,067 shares of the company's stock, valued at approximately $582,350.31. This represents a 23.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Brian Poff sold 7,739 shares of the company's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $116.82, for a total transaction of $904,069.98. Following the completion of the sale, the executive vice president directly owned 56,980 shares of the company's stock, valued at $6,656,403.60. The trade was a 11.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,310 shares of company stock valued at $3,958,375. Insiders own 4.50% of the company's stock.

Institutional Investors Weigh In On Addus HomeCare

A number of institutional investors and hedge funds have recently made changes to their positions in ADUS. State of Wyoming acquired a new position in shares of Addus HomeCare during the second quarter worth about $47,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Addus HomeCare during the first quarter worth about $41,000. Raymond James Financial Inc. acquired a new position in shares of Addus HomeCare during the second quarter worth about $61,000. CWM LLC increased its stake in shares of Addus HomeCare by 25.3% during the second quarter. CWM LLC now owns 554 shares of the company's stock worth $64,000 after acquiring an additional 112 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Addus HomeCare by 560.0% during the second quarter. EverSource Wealth Advisors LLC now owns 561 shares of the company's stock worth $65,000 after acquiring an additional 476 shares during the period. 95.35% of the stock is owned by hedge funds and other institutional investors.

About Addus HomeCare

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.